News
The day at a glance · 4 min read
Mood · Risk-On
+68
Sentiment, −100 to +100
Cyclic Peptide Library Market 2026
$3.75B
Cyclic Peptide Library Market 2032
$9.86B+16.32% CAGR
Cell Line Generation Market 2026
$1.42B
Key driverMultiple research markets tracking double-digit CAGRs as AI-enabled drug discovery and automated cell line generation gain traction across major pharmaceutical companies.
Daily briefHealthcare· Money365.Market AI ·

Healthcare Tools & Tech Markets Surge on AI Integration

Research market forecasts show double-digit growth as AI, CRISPR automation reshape biopharma workflows; Dexcom expands diabetes monitoring globally.

Biopharma Research Tools Markets Accelerate

Bullish

Cell Line Generation Market 2032

$2.67B+10.86% CAGR

Magnetic Beads Market 2025

$3.3B

Magnetic Beads Market 2032

$7.4B
PFEMRKTMO
Pfizer ($PFE), Merck ($MRK), and Thermo Fisher Scientific ($TMO) face intensifying competition across multiple research tool markets experiencing double-digit growth trajectories. The global cyclic peptide library market is projected to grow from $3.75 billion in 2026 to $9.86 billion by 2032, representing a compound annual growth rate of 16.32%, according to a market outlook released today by ResearchAndMarkets.com. AI-enabled discovery platforms are fueling demand as companies including PeptiDream, Bicycle Therapeutics, Pfizer ($PFE), and Roche advance competition in the space.
Merck ($MRK), Thermo Fisher Scientific ($TMO), Lonza, and WuXi Biologics are advancing innovation in the global cell line generation market, which ResearchAndMarkets.com projects will reach $1.42 billion in 2026 and grow at a CAGR of 10.86% to $2.67 billion by 2032. AI, CRISPR, and automation technologies are driving expansion, with the report recommending standardized quality control, auditable automation, validated AI systems, and diversified reagent sourcing to boost return on investment.
Thermo Fisher Scientific ($TMO), Merck ($MRK) KGaA, QIAGEN, Bio-Rad Laboratories, and Miltenyi Biotec are competing for leadership in the global magnetic beads market, which was valued at an estimated $3.3 billion in 2025 and is projected to reach $7.4 billion by 2032. Demand is rising in diagnostics, precision medicine, and biopharma research as nanotechnology, automation, and AI unlock targeted therapies and high-throughput workflows.

Medical Devices & Diagnostics Expansion

Bullish
DXCM
DexCom ($DXCM) announced the Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets. The glucose biosensor common stock issuer released its "Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" ahead of the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan, running September 28 through October 2.
DexCom ($DXCM) also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk. The report reveals what the company describes as a critical opportunity for global diabetes care, though specific data points from the study were not disclosed in today's announcement.

Big Pharma Pipeline & Approvals

Bullish
LLYMRNA
Eli Lilly ($LLY) announced on September 25 that the U.S. FDA approved Olumiant (baricitinib), a once-daily pill, for pediatric patients 12 years of age and older with severe alopecia areata. The decision expands Olumiant's label beyond established adult indications in moderately to severely active rheumatoid arthritis and severe alopecia areata, enlarging its addressable patient population.
Moderna ($MRNA) common stock surged to a 52-week high last week as investors rewarded the company for strong drug development momentum, according to market commentary. Laidlaw analyst Yale Jen flagged possible data in other cancers from 2027, while warning that personalized manufacturing costs, capacity, and reimbursement could limit commercial success. The analyst called China's AI drug lead claim "baseless" as Moderna ($MRNA) awaits additional cancer data.

Healthcare Services & Managed Care

Neutral

CorVel FY2026 Revenue

$959M
UNH
CorVel Corporation (NASDAQ:CRVL) has expanded its risk management and healthcare cost containment business to nearly $959 million in annual revenue in fiscal 2026. The company's capital-light model generates high returns on invested capital while converting a substantial percentage of earnings into cash, according to market analysis discussing its position within the insurance claims infrastructure serving companies including UnitedHealth ($UNH).

Looking Ahead

Neutral
DXCMMRNA
The European Association for the Study of Diabetes annual meeting runs through October 2 in Milan, where DexCom ($DXCM) is presenting its Type 2 diabetes access report and showcasing continuous glucose monitoring technology. Market research firms are forecasting sustained double-digit growth across multiple biopharma research tool segments through 2032, driven by AI integration, automation advances, and expanding applications in precision medicine and diagnostics.
Investor focus on Moderna ($MRNA) centers on anticipated cancer trial data releases, with analysts flagging 2027 as a potential timeline for additional oncology readouts. Manufacturing scalability, reimbursement pathways, and personalized medicine economics remain key variables for commercialization success across the biotech sector's next-generation therapeutic platforms.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy